Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Richard S. Shames sold 2,017 shares of the stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $19.00, for a total value of $38,323.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Richard S. Shames also recently made the following trade(s):

  • On Tuesday, September 12th, Richard S. Shames sold 3,687 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $14.31, for a total value of $52,760.97.
  • On Tuesday, August 29th, Richard S. Shames sold 1,512 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $17.00, for a total value of $25,704.00.

Protagonist Therapeutics, Inc. (NASDAQ PTGX) traded up 3.20% on Tuesday, hitting $19.67. The stock had a trading volume of 34,435 shares. Protagonist Therapeutics, Inc. has a 1-year low of $8.00 and a 1-year high of $26.36. The stock’s 50-day moving average is $16.36 and its 200 day moving average is $12.64. The firm’s market capitalization is $332.46 million.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, August 8th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.70).

COPYRIGHT VIOLATION WARNING: “Protagonist Therapeutics, Inc. (PTGX) Insider Sells $38,323.00 in Stock” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/10/protagonist-therapeutics-inc-ptgx-insider-sells-38323-00-in-stock.html.

Several research firms have weighed in on PTGX. Zacks Investment Research raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Friday, August 18th. ValuEngine cut Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 11th. Finally, BTIG Research initiated coverage on Protagonist Therapeutics in a research report on Friday, July 21st. They set a “buy” rating and a $36.00 price target on the stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers bought a new stake in Protagonist Therapeutics during the 2nd quarter valued at $114,000. Teachers Advisors LLC boosted its position in Protagonist Therapeutics by 71.4% during the 2nd quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after acquiring an additional 6,757 shares in the last quarter. Northern Capital Management LLC bought a new stake in Protagonist Therapeutics during the 2nd quarter valued at $188,000. California State Teachers Retirement System boosted its position in Protagonist Therapeutics by 8.5% during the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after acquiring an additional 1,300 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in Protagonist Therapeutics by 19.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock valued at $264,000 after acquiring an additional 3,812 shares in the last quarter. 48.04% of the stock is currently owned by institutional investors and hedge funds.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.